//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts









Loading...
Who's really in the loop? Rethinking oversight in AI-assisted health care đź”— spkl.io/633277BQYt
3d
Behind every paper at The Lancet Group are layers of editorial scrutiny and integrity checks. âś… Learn how we work with authors and teams around the world to support trustworthy research: spkl.io/6332576U3b
6d
đź“– Explore the full issue: tinyurl.com/yt8nkd3h
Foodborne illnesses caused 1.5 million deaths and cost US$647 billion in economic losses in 2021, new analysis estimates in @lancetgh.bsky.social Read now 👉 spkl.io/633257Bk5V
The Lancet
Ebola is testing global health—again A growing outbreak in DR Congo & Uganda is exposing: - Fragile health systems - Gaps in preparedness - Risks to health-care workers And there is still no licensed vaccine for this strain. Find out more: spkl.io/633237Bv4v
Presented today at #ERA2026, the INFINITY trial found that finerenone reduced the risk of chronic kidney disease progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death. Explore the research: spkl.io/633287Badg
Presented today at #ERA2026 ⤵️ Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial 🔗 spkl.io/633257BZOL
An immunotherapy warrants further investigation as a treatment for severe #hantavirus pulmonary syndrome, early evidence from 10 patients suggests. Find out more in @thelancetinfdis.bsky.social spkl.io/633217Bkbc
🆕 Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson’s disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study spkl.io/6332076Ohi
Chronic kidney disease (#CKD) affects 788–844 million adults worldwide — and is projected to become the fifth leading cause of death by 2040. A new Series, presented today at #ERA2026, examines what is needed to change this trajectory: spkl.io/63321765k5
5d
4d
5d
5d
6d
7d
7d
7d
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
The Lancet
Explore the current issue of The Lancet, a world leading medical journal published weekly since 1823
tinyurl.com
The Lancet, 06 June 2026, Volume 407, Issue 10545, Pages 2263-2344